Javascript must be enabled to continue!
Bulimia: Independence of Antibulimic and Antidepressant Properties of Desipramine
View through CrossRef
The purpose of this study was to identify variables useful for predicting a positive response to the tricyclic antidepressant desipramine, amongst bulimic subjects. Using a randomized double-blind cross-over design, 24 normal weight bulimics completed a 15-week protocol in which they received either desipramine (150 mg/day)for six weeks, no drug for three weeks, followed by placebo for six weeks, or the reverse sequence. At weeks 0, 2, 4, 6, 9, 11, 13, and 15, each subject was assessed using the EDI, SCL-90, POMS and binge records. The DST, Diagnostic Interview Schedule (DIS), and a personal and family medical-psychiatric history questionnaire were administered at initial assessment, while plasma desipramine levels were obtained at weeks 4 and 13. Responders were defined in terms of both binge frequency reduction, and decrease in depressive symptoms.
In the sample of 24 subjects, desipramine was significantly more effective than placebo in reducing the frequency of weekly hinging and vomiting, as well as causing a reduction in the fatigue scale of the POMS. No significant effect of the drug was obtained on the EDI or the SCL-90. In terms of reduction in binge frequency, seven responders were identified; another seven were found to be borderline responders, while 10 were labeled as non-responders. The three groups did not differ in terms of their initial scores on the SCL-90, POMS, DST, DIS results, or psychological subscales of the EDI. However, responders were found to have lower EDI bulimia subscale scores, but a higher frequency of purging episodes than were non-responders. Eight patients were identified as borderline responders with respect to depressive symptoms. They differed from depression non-responders in that they had abnormal DST results, and were more likely to report a family history of depression. These results indicate that the predictors of the antibulimic effect of desipramine in bulimia are independent of its antidepressant properties.
SAGE Publications
Title: Bulimia: Independence of Antibulimic and Antidepressant Properties of Desipramine
Description:
The purpose of this study was to identify variables useful for predicting a positive response to the tricyclic antidepressant desipramine, amongst bulimic subjects.
Using a randomized double-blind cross-over design, 24 normal weight bulimics completed a 15-week protocol in which they received either desipramine (150 mg/day)for six weeks, no drug for three weeks, followed by placebo for six weeks, or the reverse sequence.
At weeks 0, 2, 4, 6, 9, 11, 13, and 15, each subject was assessed using the EDI, SCL-90, POMS and binge records.
The DST, Diagnostic Interview Schedule (DIS), and a personal and family medical-psychiatric history questionnaire were administered at initial assessment, while plasma desipramine levels were obtained at weeks 4 and 13.
Responders were defined in terms of both binge frequency reduction, and decrease in depressive symptoms.
In the sample of 24 subjects, desipramine was significantly more effective than placebo in reducing the frequency of weekly hinging and vomiting, as well as causing a reduction in the fatigue scale of the POMS.
No significant effect of the drug was obtained on the EDI or the SCL-90.
In terms of reduction in binge frequency, seven responders were identified; another seven were found to be borderline responders, while 10 were labeled as non-responders.
The three groups did not differ in terms of their initial scores on the SCL-90, POMS, DST, DIS results, or psychological subscales of the EDI.
However, responders were found to have lower EDI bulimia subscale scores, but a higher frequency of purging episodes than were non-responders.
Eight patients were identified as borderline responders with respect to depressive symptoms.
They differed from depression non-responders in that they had abnormal DST results, and were more likely to report a family history of depression.
These results indicate that the predictors of the antibulimic effect of desipramine in bulimia are independent of its antidepressant properties.
Related Results
Treatment of Bulimia with Desipramine: A Double-Blind Crossover Study
Treatment of Bulimia with Desipramine: A Double-Blind Crossover Study
The purpose of this study was to evaluate the effect of desipramine, a tricyclic antidepressant with relatively specific noradrenergic effects, on bulimic behaviour, eating attitud...
Bulimia and major affective disorder: experience with 105 patients
Bulimia and major affective disorder: experience with 105 patients
SummarySeveral lines of evidence suggest that bulimia - the syndrome of compulsive binge-eating - may be related to major affective disorder. First, high rates of major affective d...
Investigation of the psychopathology of purging bulimia and binge eating disorder
Investigation of the psychopathology of purging bulimia and binge eating disorder
The new addition of nonpurging bulimia to the DSM-IV created a significant controversy among eating disorder experts. Many argued that nonpurging bulimia was in fact a subtype of b...
Inhibition of nonexocytotic norepinephrine release by desipramine reduces myocardial infarction size
Inhibition of nonexocytotic norepinephrine release by desipramine reduces myocardial infarction size
During myocardial ischemia, a substantial accumulation of norepinephrine occurs in the ischemic zone due to a local nonexocytotic release of norepinephrine. Norepinephrine release ...
Individual and sex differences in antidepressant drug response
Individual and sex differences in antidepressant drug response
Major depression is associated with both dysregulation of the hypothalamic pituitary adrenal (HPA) axis and serotonergic deficiency. Women experience major depression at roughly tw...
1764 – Case Report: Antidepressant Withdrawal Mania
1764 – Case Report: Antidepressant Withdrawal Mania
IntroductionAntidepressant withdrawal mania is a rare paradoxical event. It was initially reported in unipolar patients but it can also occur in bipolar patients, despite adequate ...
Use of antidepressant serotoninergic medications and cardiac valvulopathy: a nested case–control study in the health improvement network (THIN) database
Use of antidepressant serotoninergic medications and cardiac valvulopathy: a nested case–control study in the health improvement network (THIN) database
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Some medications can induce cardiac valvulopathy by acting on 5‐HT2B receptors.• Antidepressant serotoninergic medications may activate 5‐...
Amygdala reactivity, antidepressant discontinuation and relapse: a longitudinal, observational study with a randomized component
Amygdala reactivity, antidepressant discontinuation and relapse: a longitudinal, observational study with a randomized component
Importance: Antidepressant discontinuation substantially increases the risk of a depression relapse. The neurobiological mechanisms through which this happens are not known. Amygda...

